<DOC>
	<DOCNO>NCT00003361</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness decitabine treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Decitabine Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response patient myelodysplastic syndrome ( include chronic myelomonocytic leukemia ) decitabine . OUTLINE : This open label , multicenter study . Patients stratified disease ( low risk myelodysplastic syndrome ( MDS ) vs. high risk MDS vs. chronic myelomonocytic leukemia ) . Patients receive decitabine 4 hour infusion every 8 hour day 1-3 . Treatment continue every 6-8 week 4-6 course . Patients follow 6 12 month . PROJECTED ACCRUAL : Approximately 75 patient accrue study 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven myelodysplastic syndrome Refractory anemia ( RA ) RA ring sideroblast ( RARS ) RA excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia ( CMML ) RA RARS : Platelet count le 50,000/mm3 CMML : If WBC great 10,000/mm3 , must least 8 % monocyte blood marrow PATIENT CHARACTERISTICS : Age : 15 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Other : No active uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception No active cancer except skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No one prior chemotherapy regimen myelodysplastic syndrome At least 3 week since chemotherapy recover No prior highdose cytarabine ( least 0.5 g/m2 least 4 dos ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>